drugset / Trial / NCT00937495
Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial is studying how well giving vorinostat together with bortezomib works in treating patients with advanced soft tissue sarcoma. Vorinostat and bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vorinostat together with bortezomib may kill more tumor cells.
Timeline
- Start
- 2009-06
- Primary completion
- 2010-08
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Intravenous |
| Subject | Vorinostat | Small molecule | 400 mg | Oral |